Figure 2.

Magnitude of initial seroconversion based on demographic information. (A) Differences between young (18–39 y.o.) and older (50+ y.o.) participants were significant in infected, unvaccinated (* p = 0.0334) and naïve, vaccinated (** p = 0.0038) groups. (B) Differences between Pfizer and Moderna vaccinees were not significant. (C) Differences between females and males were significant in the naïve, vaccinated (* p = 0.0438) group. (D) Differences between participants with a healthy weight (BMI = 18.5–24.9) and those who were obese (BMI ≥ 30) were significant in the naïve, vaccinated group (* p = 0.0119). Initial seroconversion is designated by timepoints 0.5–1 month after COVID-19 infection or the reception of the primary vaccine series (2 × mRNA or 1 × viral vector).